{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T17:42:04Z","timestamp":1774374124210,"version":"3.50.1"},"reference-count":84,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","cancertreatmentreviews.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.ctrv.2016.10.004","type":"journal-article","created":{"date-parts":[[2016,10,27]],"date-time":"2016-10-27T22:16:31Z","timestamp":1477606591000},"page":"46-53","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"special_numbering":"C","title":["Bone health in the elderly cancer patient: A SIOG position paper"],"prefix":"10.1016","volume":"51","author":[{"given":"J.J.","family":"Body","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Terpos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Tombal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Hadji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Arif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Aapro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2016.10.004_b0005","doi-asserted-by":"crossref","first-page":"11089","DOI":"10.1158\/0008-5472.CAN-06-2407","article-title":"Preparing the \u2018soil\u2019: the premetastatic niche","volume":"66","author":"Kaplan","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2016.10.004_b0010","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nrc3055","article-title":"Cancer to bone: a fatal attraction","volume":"11","author":"Weilbaecher","year":"2011","journal-title":"Nat Rev Cancer"},{"issue":"Suppl. 20","key":"10.1016\/j.ctrv.2016.10.004_b0015","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2016.10.004_b0020","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s10549-011-1475-5","article-title":"Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999\u20132007)","volume":"129","author":"Yong","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2016.10.004_b0025","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00198-012-2074-y","article-title":"European guidance for the diagnosis and management of osteoporosis in postmenopausal women","volume":"24","author":"Kanis","year":"2013","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.ctrv.2016.10.004_b0030","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1007\/s00198-006-0172-4","article-title":"An estimate of the worldwide prevalence and disability associated with osteoporotic fractures","volume":"17","author":"Johnell","year":"2006","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.ctrv.2016.10.004_b0035","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S8756-3282(01)00614-7","article-title":"Epidemiology of fracture in England and Wales","volume":"29","author":"Van Staa","year":"2001","journal-title":"Bone"},{"key":"10.1016\/j.ctrv.2016.10.004_b0040","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s001980070064","article-title":"Long-term risk of osteoporotic fracture in Malmo","volume":"11","author":"Kanis","year":"2000","journal-title":"Osteop Int"},{"key":"10.1016\/j.ctrv.2016.10.004_b0045","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1359\/JBMR.050304","article-title":"Predictive value of BMD for hip and other fractures","volume":"20","author":"Johnell","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ctrv.2016.10.004_b0050","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00198-004-1780-5","article-title":"Assessment of fracture risk","volume":"16","author":"Kanis","year":"2005","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.ctrv.2016.10.004_b0055","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00198-007-0343-y","article-title":"The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women","volume":"18","author":"Kanis","year":"2007","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.ctrv.2016.10.004_b0060","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1093\/annonc\/mdn164","article-title":"Practical guidance for the management of aromotase inhibitor-associated bone loss","volume":"19","author":"Hadji","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2016.10.004_b0065","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S0140-6736(15)60908-4","article-title":"Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials","volume":"386","author":"Coleman","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2016.10.004_b0070","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.ejca.2012.12.027","article-title":"Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012","volume":"49","author":"Ferlay","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2016.10.004_b0075","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1586\/era.10.94","article-title":"Outcomes following adjuvant therapy for HER2-positive early breast cancer in the elderly","volume":"10","author":"Otter","year":"2010","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.ctrv.2016.10.004_b0080","unstructured":"http:\/\/seer.cancer.gov\/statfacts\/html\/breast.html."},{"key":"10.1016\/j.ctrv.2016.10.004_b0085","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/S0140-6736(09)61460-4","article-title":"Ageing populations: the challenges ahead","volume":"374","author":"Christensen","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2016.10.004_b0090","first-page":"1","article-title":"Menopausal symptoms and adjuvant therapy-associated adverse events","volume":"15","author":"Hadji","year":"2007","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ctrv.2016.10.004_b0095","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1111\/j.1532-5415.2012.04107.x","article-title":"Systematic review of bone health in older women treated with aromatase inhibitors for early stage breast cancer","volume":"60","author":"Becker","year":"2012","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.ctrv.2016.10.004_b0100","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1634\/theoncologist.11-10-1121","article-title":"Bone loss and fracture risk associated with cancer therapy","volume":"11","author":"Guise","year":"2006","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2016.10.004_b0105","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1470-2045(11)70389-8","article-title":"Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial","volume":"13","author":"Cheung","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2016.10.004_b0110","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s10549-015-3661-3","article-title":"The impact of compliance on fracture risk in women with breast cancer in the United Kingdom treated with aromatase inhibitors","volume":"155","author":"Schmidt","year":"2016","journal-title":"Br Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2016.10.004_b0115","doi-asserted-by":"crossref","first-page":"380","DOI":"10.7326\/0003-4819-152-6-201003160-00008","article-title":"Meta-analysis: excess mortality after hip fracture among older women and men","volume":"152","author":"Haentjens","year":"2010","journal-title":"Ann Int Med"},{"key":"10.1016\/j.ctrv.2016.10.004_b0120","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1503\/cmaj.081720","article-title":"Relation between fractures and mortality: results from the Canadian Multicenter Osteoporosis Study","volume":"181","author":"Ioannidis","year":"2009","journal-title":"CMAJ"},{"key":"10.1016\/j.ctrv.2016.10.004_b0125","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/annonc\/mds277","article-title":"Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results","volume":"24","author":"Coleman","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2016.10.004_b0130","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1200\/JCO.2008.16.3832","article-title":"Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for non-metastatic breast cancer","volume":"26","author":"Ellis","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2016.10.004_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(15)60995-3","article-title":"Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial","author":"Gnant","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2016.10.004_b0140","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S0140-6736(15)60908-4","article-title":"Effects of bisphosphonate treatment on recurrence and cause-specific mortality in women with early breast cancer: a meta-analysis of individual patient data from randomised trials","volume":"386","author":"Coleman","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2016.10.004_b0145","doi-asserted-by":"crossref","unstructured":"Gnant M, Pfeiler G, Dubsky PC, et al. The impact of adjuvant denosumab on disease-free survival: results from 3,425 postmenopausal patients of the ABCSG-18 trial. In: S2\u201302 2015 San Antonio breast cancer symposium.","DOI":"10.1200\/jco.2015.33.15_suppl.504"},{"key":"10.1016\/j.ctrv.2016.10.004_b0150","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdu103","article-title":"Bone health in cancer patients: ESMO clinical practice guidelines","author":"Coleman","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2016.10.004_b0155","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/annonc\/mdv617","article-title":"Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European panel","volume":"27","author":"Hadji","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2016.10.004_b0160","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1210\/jc.2011-3045","article-title":"Osteoporosis in men: an Endocrine Society Practical Guideline","volume":"97","author":"Watts","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ctrv.2016.10.004_b0165","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.amepre.2009.01.013","article-title":"Screening for osteoporosis in the adult U.S. population: the ACPM position statement on preventive practice","volume":"36","author":"Lim","year":"2009","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.ctrv.2016.10.004_b0170","unstructured":"http:\/\/seer.cancer.gov\/statfacts\/html\/prost.html."},{"key":"10.1016\/j.ctrv.2016.10.004_b0175","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.juro.2010.04.068","article-title":"Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 men","volume":"184","author":"Alibhai","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.ctrv.2016.10.004_b0180","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/pds.2258","article-title":"Timing of androgen deprivation therapy use and fracture risk among elderly man with prostate cancer in the United States","volume":"21","author":"Beebe-Dimmer","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.ctrv.2016.10.004_b0185","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMoa041943","article-title":"Risk of fracture after androgen deprivation for prostate cancer","volume":"352","author":"Shahinian","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2016.10.004_b0190","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/annonc\/mds216","article-title":"Management and challenges of corticosteroid therapy in men with metastatic castrate-resistant prostate cancer","volume":"24","author":"Dorff","year":"2013","journal-title":"Ann Oncol"},{"issue":"Suppl. 10","key":"10.1016\/j.ctrv.2016.10.004_b0195","doi-asserted-by":"crossref","first-page":"x251","DOI":"10.1093\/annonc\/mds325","article-title":"Non-metastatic CRPC and asymptomatic metastatic CRPC: which treatment for which patients?","author":"Tombal","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2016.10.004_b0200","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/bjc.2013.340","article-title":"Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer","volume":"109","author":"Pezaro","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2016.10.004_b0205","doi-asserted-by":"crossref","first-page":"416","DOI":"10.7326\/0003-4819-146-6-200703200-00006","article-title":"Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized controlled trial","volume":"146","author":"Greenspan","year":"2007","journal-title":"Ann Int Med"},{"key":"10.1016\/j.ctrv.2016.10.004_b0210","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMoa0809003","article-title":"Denosumab in men receiving androgen-deprivation therapy for prostate cancer","volume":"361","author":"Smith","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2016.10.004_b0215","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jbo.2012.04.002","article-title":"A review of recently published radiotherapy treatment guidelines for bone metastases: contrasts or convergence?","volume":"1","author":"Lutz","year":"2012","journal-title":"J Bone Oncol"},{"key":"10.1016\/j.ctrv.2016.10.004_b0220","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.ejca.2006.12.006","article-title":"International Society of Geriatric Oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients","volume":"43","author":"Body","year":"2007","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2016.10.004_b0225","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/978-3-642-21892-7_8","article-title":"Perspectives in the elderly patient: benefits and limits of bisphosphonates and denosumab","volume":"192","author":"Santini","year":"2012","journal-title":"Rec Results Cancer Res"},{"key":"10.1016\/j.ctrv.2016.10.004_b0230","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1007\/s00520-013-1932-2","article-title":"Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid","volume":"21","author":"von Moos","year":"2013","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ctrv.2016.10.004_b0235","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2016.10.004_b0240","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1200\/JCO.2010.32.5209","article-title":"American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer","volume":"29","author":"Van Poznak","year":"2011","journal-title":"J Clin Oncol"},{"issue":"Suppl. 3","key":"10.1016\/j.ctrv.2016.10.004_b0245","doi-asserted-by":"crossref","first-page":"iii124","DOI":"10.1093\/annonc\/mdu103","article-title":"Bone health in cancer patients: ESMO clinical practice guidelines","volume":"25","author":"Coleman","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2016.10.004_b0250","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(13)70174-8","article-title":"Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial","volume":"14","author":"Amadori","year":"2013","journal-title":"Lancet Oncol"},{"issue":"Suppl.; Abstr. LBA9500","key":"10.1016\/j.ctrv.2016.10.004_b0255","first-page":"5s","article-title":"Efficacy and safety of continued zoledronic acid every 4 weeks versus every 12 weeks in women with bone metastases from breast cancer: results of the OPTIMIZE-2 trial","volume":"32","author":"Hortobagyi","year":"2014","journal-title":"J Clin Oncol"},{"issue":"Suppl.; Abstr. 9501","key":"10.1016\/j.ctrv.2016.10.004_b0260","article-title":"CALGB 90604 (Alliance): a randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer (abstr)","volume":"33","author":"Himelstein","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2016.10.004_b0265","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2165\/11598090-000000000-00000","article-title":"Population pharmacokinetic analysis of denosumab in patients with bone metastases from solid tumours","volume":"51","author":"Gibiansky","year":"2012","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ctrv.2016.10.004_b0270","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1210\/jc.2010-1502","article-title":"Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass","volume":"96","author":"Bone","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ctrv.2016.10.004_b0275","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","article-title":"Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials","volume":"48","author":"Lipton","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2016.10.004_b0280","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1016\/j.ejca.2015.05.016","article-title":"Hypocalcaemia in patients with metastastic bone disease treated with denosumab","volume":"51","author":"Body","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2016.10.004_b0285","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research","volume":"22","author":"Khosla","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ctrv.2016.10.004_b0290","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nrendo.2010.195","article-title":"Osteonecrosis of the jaw and bisphosphonates in cancer: a narrative review","volume":"7","author":"Migliorati","year":"2011","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.ctrv.2016.10.004_b0295","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","article-title":"Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases","volume":"23","author":"Saad","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2016.10.004_b0300","unstructured":"seer.cancer.gov\/statfacts\/html\/mulmy.html [accessed 29.9.2015]."},{"key":"10.1016\/j.ctrv.2016.10.004_b0305","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group Report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2016.10.004_b0310","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2012.47.7901","article-title":"International myeloma working group recommendations for the treatment of myeloma-related bone disease","author":"Terpos","year":"2013","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2016.10.004_b0315","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.3324\/haematol.2014.117176","article-title":"European myeloma network guidelines for the management of multiple MYELOMA-related complications","volume":"100","author":"Terpos","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.ctrv.2016.10.004_b0320","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s00432-013-1427-z","article-title":"Persistence with bisphosphonates in patients with metastatic breast cancer: a retrospective database analysis","volume":"139","author":"Hadji","year":"2013","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ctrv.2016.10.004_b0325","unstructured":"Jacob L, Hadji P, Kostev K. Age-related differences in persistency with bisphosphonates in women with breast cancer. 2015 submitted to IJGO."},{"key":"10.1016\/j.ctrv.2016.10.004_b0330","doi-asserted-by":"crossref","first-page":"A657","DOI":"10.1016\/j.jval.2015.09.2377","article-title":"GRAND-4: the German retrospective analysis on persistence in women with osteoporosis treated with bisphosphonates or denosumab","volume":"18","author":"Hadji","year":"2015","journal-title":"Value Health"},{"key":"10.1016\/j.ctrv.2016.10.004_b0335","doi-asserted-by":"crossref","first-page":"E31","DOI":"10.1188\/15.CJON.E31-E35","article-title":"Nursing management of patients with castration-resistant prostate cancer undergoing radium-223 dichloride treatment","volume":"19","author":"Delacruz","year":"2015","journal-title":"Clin J Oncol Nurs"},{"issue":"Suppl. 1","key":"10.1016\/j.ctrv.2016.10.004_b0340","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/S1462-3889(14)70003-1","article-title":"Metastatic castration-resistant prostate cancer. Part 2: helping patients make informed choices and managing treatment side effects","volume":"17","author":"Sonnek","year":"2013","journal-title":"Eur J Oncol Nurs"},{"issue":"Suppl. 2","key":"10.1016\/j.ctrv.2016.10.004_b0345","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/j.ejon.2007.07.004","article-title":"Role of the nurse in preserving patients\u2019 independence","volume":"11","author":"Maxwell","year":"2007","journal-title":"Eur J Oncol Nurs"},{"key":"10.1016\/j.ctrv.2016.10.004_b0350","doi-asserted-by":"crossref","first-page":"49","DOI":"10.7748\/ns.25.40.49.s50","article-title":"Treatment and care of patients with metastatic breast cancer","volume":"25","author":"Beaumont","year":"2011","journal-title":"Nurs Stand"},{"key":"10.1016\/j.ctrv.2016.10.004_b0355","doi-asserted-by":"crossref","first-page":"48","DOI":"10.7748\/ns2013.01.27.19.48.c9499","article-title":"Cancer-induced bone disease","volume":"27","author":"Drudge-Coates","year":"2013","journal-title":"Nurs Stand"},{"key":"10.1016\/j.ctrv.2016.10.004_b0360","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/NOR.0b013e31829a4da3","article-title":"Managing bone metastasis in the patient with advanced cancer","volume":"32","author":"Monczewski","year":"2013","journal-title":"Orthop Nurs"},{"key":"10.1016\/j.ctrv.2016.10.004_b0365","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1200\/JCO.2004.06.140","article-title":"Randomized clinical trial of the effectiveness of a self-care intervention to improve cancer pain management","volume":"22","author":"Miaskowski","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2016.10.004_b0370","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/NCC.0b013e3182948418","article-title":"A randomized clinical trial of the efficacy of a self-care intervention to improve cancer pain management","volume":"37","author":"Rustoen","year":"2014","journal-title":"Cancer Nurs"},{"key":"10.1016\/j.ctrv.2016.10.004_b0375","doi-asserted-by":"crossref","first-page":"162","DOI":"10.12968\/bjcn.2015.20.4.162","article-title":"Recognising metastatic spinal cord compression","volume":"20","author":"Bowers","year":"2015","journal-title":"Br J Commun Nurs"},{"key":"10.1016\/j.ctrv.2016.10.004_b0380","unstructured":"Coleman RC, Van Poznak C, <http:\/\/www.uptodate.com\/contents\/osteoclast-inhibitors-for-patients-with-bone-metastases-from-breast-prostate-and-other-solid-tumors>, 2015."},{"key":"10.1016\/j.ctrv.2016.10.004_b0390","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1188\/03.CJON.403-408","article-title":"Advances in supportive care of patients with cancer and bone metastases: nursing implications of zoledronic acid","volume":"7","author":"Maxwell","year":"2003","journal-title":"Clin J Oncol Nurs"},{"issue":"75","key":"10.1016\/j.ctrv.2016.10.004_b0395","first-page":"584","article-title":"Bone-targeted therapy","volume":"2015","author":"Salmen","year":"2015","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"10.1016\/j.ctrv.2016.10.004_b0400","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2013-202861","article-title":"Denosumab should be the treatment of choice for bisphosphonate refractory hypercalcaemia of malignancy","author":"Adhikaree","year":"2014","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.ctrv.2016.10.004_b0405","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/j.clgc.2013.06.002","article-title":"Use of denosumab for renal cell carcinoma-associated malignant hypercalcemia: a case report and review of the literature","volume":"11","author":"Freeman","year":"2013","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.ctrv.2016.10.004_b0410","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1002\/jbmr.1613","article-title":"A single-dose study of denosumab in patients with various degrees of renal impairment","volume":"27","author":"Block","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ctrv.2016.10.004_b0415","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/pcan.2013.22","article-title":"Safety and efficacy of resistance exercise in prostate cancer patients with bone metastases","volume":"16","author":"Cormie","year":"2013","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.ctrv.2016.10.004_b0420","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.radonc.2014.06.008","article-title":"The effect of resistance training during radiotherapy on spinal bone metastases in cancer patients \u2013 a randomized trial","volume":"112","author":"Rief","year":"2014","journal-title":"Radiother Oncol"},{"issue":"Suppl. 3","key":"10.1016\/j.ctrv.2016.10.004_b0440","doi-asserted-by":"crossref","first-page":"iii124","DOI":"10.1093\/annonc\/mdu103","article-title":"Bone health in cancer patients: ESMO clinical practice guidelines","volume":"25","author":"Coleman","year":"2014","journal-title":"Ann Oncol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737216301049?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737216301049?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,15]],"date-time":"2019-09-15T03:33:27Z","timestamp":1568518407000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737216301049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":84,"alternative-id":["S0305737216301049"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2016.10.004","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bone health in the elderly cancer patient: A SIOG position paper","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2016.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}